NASDAQ:EDSA
Edesa Biotech, Inc. Stock News
$4.53
+0.0950 (+2.14%)
At Close: May 14, 2024
Edesa Biotech Extends Dermatitis Study to Canada
08:10am, Tuesday, 13'th Jul 2021
TORONTO, ON / ACCESSWIRE / July 13, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the c
EDSA Stock Price Increases Over 14% Pre-Market: Why It Happened
08:17am, Friday, 18'th Jun 2021
The stock price of Edesa Biotech Inc (NASDAQ: EDSA) increased by over 14% pre-market. This is why it happened.
Edesa Biotech Reports Favorable Review of COVID-19 Study
07:45am, Friday, 18'th Jun 2021
TORONTO, ON / ACCESSWIRE / June 18, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported that an ind
Edesa Biotech to Attend BIO Digital 2021
08:00am, Tuesday, 08'th Jun 2021
TORONTO, ON / ACCESSWIRE / June 8, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the co
Edesa Biotech's EB01 Shows Encouraging Interim Results In Dermatitis Trial
08:47am, Thursday, 03'rd Jun 2021
Edesa Biotech Inc's (NASDAQ: EDSA) EB01 has met a key interim study parameter as part of an adaptive Phase 2b trial evaluating EB01 as monotherapy for moderate to severe chronic Allergic Contact
Edesa Biotech Reports Positive Interim Results in Dermatitis Trial
07:30am, Thursday, 03'rd Jun 2021
TORONTO, ON / ACCESSWIRE / June 3, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the co
Edesa Biotech to Join Panel Discussion at Industry Event
08:00am, Friday, 28'th May 2021
TORONTO, ON / ACCESSWIRE / May 28, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to
Edesa Biotech Reports Fiscal 2nd Quarter 2021 Results
08:00am, Friday, 14'th May 2021
TORONTO, ON / ACCESSWIRE / May 14, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial re
Edesa Biotech Reaches Enrollment Milestone in COVID Study
08:10am, Monday, 15'th Mar 2021
TORONTO, ON / ACCESSWIRE / March 15, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it h
Edesa Biotech Completes Enrollment for Interim Clinical Study Milestone
07:30am, Tuesday, 09'th Mar 2021
TORONTO, ON / ACCESSWIRE / March 9, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it ha
Edesa Biotech Announces Closing of $10 Million Bought Deal Offering of Common Shares
04:10pm, Tuesday, 02'nd Mar 2021
TORONTO, ON / ACCESSWIRE / March 2, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the closin
EDSA Stock Price Increases Over 77% Pre-Market: Why It Happened
08:50am, Tuesday, 26'th Jan 2021
The stock price of Edesa Biotech Inc (NASDAQ: EDSA) increased by over 77% pre-market. This is why it happened.
Edesa Biotech Expands COVID-19 Clinical Study to Colombia
07:30am, Monday, 11'th Jan 2021
TORONTO, ON / ACCESSWIRE / January 11, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received approval from the Ministry of Health (INVIMA) in Colombia to e
Edesa Biotech Issues Letter to Shareholders
08:00am, Wednesday, 30'th Dec 2020
TORONTO, ON / ACCESSWIRE / December 30, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, issued a letter to shareholders from its Chief Executive Officer, Par Nijh
Edesa Biotech Reports Fiscal 3rd Quarter 2020 Results
11:45am, Wednesday, 12'th Aug 2020
TORONTO, ON / ACCESSWIRE / August 12, 2020 / Edesa Biotech, Inc.
